"The BMS Industry Partnership Office, which actively facilitates collaborations with the different research and clinical institutions is an excellent example of how Singapore is making the environment even more conducive for industry to conduct translational research here," he added.

Mr Thomas Steffen, country division head, Bayer HealthCare Pharmaceuticals, Singapore, Malaysia and Brunei, said, "Singapore is uniquely positioned as a research hub for Bayer HealthCare. We have access to the key ethnic groups in Asia, which affords us greater clinical insights to the disease biology of Asian prevalent cancers and a growing pool of translational and clinical research talents with access to the necessary research facilities and scientific infrastructure."